Michael R. Hayden - 31 Dec 2022 Form 5 Insider Report for IONIS PHARMACEUTICALS INC (IONS)

Role
Director
Signature
Patrick R. O'Neil, attorney-in-fact, Michael R. Hayden
Issuer symbol
IONS
Transactions as of
31 Dec 2022
Transactions value $
$0
Form type
5
Date filed
14 Feb 2023, 15:53
Previous filing
05 Dec 2022
Next filing
13 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding IONS Common Stock 23.1K 31 Dec 2022 Direct
holding IONS Common Stock 2K 31 Dec 2022 By Wife F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These securities are held by Genworks 2 Consulting, Inc. ("Genworks 2"). The Reporting Person's spouse has sole voting and investment power with respect to the shares held by Genworks 2. Genworks 2 owned such shares of common stock on September 20, 2018, the date on which the reporting person became a director of Ionis Pharmaceuticals, Inc.